Skip to main content
. 2021 Aug 4;12(8):1206. doi: 10.3390/genes12081206

Figure 3.

Figure 3

Single-cell sequencing-guided biomimetic-based miR-delivery. After identifying the tumoral antigen based on single-cell sequencing data and fabricating related receptor/CAR/TCR on the biomimetic carriers, the delivery of the PD-L1-inhibiting miRs can substantially stimulate anti-tumoral immune responses, activate apoptosis of tumoral cells, inhibit tumor proliferation, suppress tumor migration, and enhance the chemosensitivity of tumoral cells to chemotherapeutic agents. Objects are obtained from https://smart.servier.com/ (accessed on 25 July 2021).